Anika Therapeutics(ANIK) - 2025 Q3 - Earnings Call Presentation

Financial Performance - Commercial Channel Revenue increased by 22% year-over-year[8] - OEM Revenue decreased by 20% due to lower pricing both in transfer units and royalties on Monovisc® and Orthovisc® sales controlled by J&J MedTech[12, 14] - Total Revenue decreased by 6% to $278 million[12, 14] - Gross Profit decreased due to lower OEM Channel revenue and higher manufacturing costs[14] - SG&A expenses decreased by 12% reflecting cost discipline[8, 12] - Adjusted EBITDA was $09 million[8] - Cash provided by operations totaled $69 million[8] Product and Pipeline Updates - Regenerative Solutions portfolio grew 25% year-over-year[8] - International OA Pain business grew 21% year-over-year[8] - Integrity Implant System continues to outpace the market with approximately 500 cases in Q3[8, 11] - Hyalofast® PMA was submitted on October 31, supported by U S Phase III data[8] Strategic Initiatives - Commenced a $15 million 10b5-1 share repurchase program[8]